StockData
Attovia Therapeutics, Inc. logo

Attovia Therapeutics, Inc. (ATTO) stock

ATTONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026
$14.86+0.13 (+0.92%)

Close on Nov 17, 2026Market cap $678.38MP/E –Yield –

Attovia Therapeutics cash

Cash and short-term investments held at the end of each period.

Attovia Therapeutics's cash was $395.94M at Sep 30, 2026. For fiscal 2025 it was $152.27M, up 387.4% from the year before.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$152.27M+387.4%
FY2024Dec 31, 2024$31.24M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$395.94M+828.5%
Q2 FY2026Jun 30, 2026$115.13M+268.6%
Q4 FY2025Dec 31, 2025$152.27M–
Q3 FY2025Sep 30, 2025$49.77M–
Q2 FY2025Jun 30, 2025$42.65M–
Q4 FY2024Dec 31, 2024$31.24M–

More Attovia Therapeutics figures

See a number that looks wrong?